Lin Yu-Hsin 4
4 · BELITE BIO, INC · Filed Apr 23, 2026
Research Summary
AI-generated summary of this filing
Belite Bio CEO Lin Yu-Hsin Receives 10,000-Share RSU Award
What Happened
Lin Yu-Hsin, CEO of Belite Bio, had 10,000 restricted stock units (RSUs) vest on April 21, 2026. The Form 4 reports an "other acquisition" of 10,000 ordinary shares at a reported price of $0.00 (i.e., shares issued on vesting), with a total reported cash value of $0.
Key Details
- Transaction date: 2026-04-21; reported on Form 4 filed 2026-04-23 (timely filing).
- Transaction type/code: Other acquisition (code J) — RSU vesting resulting in issuance of 10,000 shares.
- Price: $0.00 per share (shares issued upon vesting, not purchased).
- Shares owned after transaction: Not disclosed in the filing.
- Footnote: RSUs were granted on 09/15/2025 and vested when performance criteria were met on 04/21/2026, causing issuance of 10,000 ordinary shares.
- No sale, tax-withholding sale, or 10b5-1 plan is indicated in the filing.
Context
This was a compensation/award-related issuance (performance-based RSU vesting), not an open-market purchase or sale. Such vesting events are routine corporate compensation and do not by themselves indicate insider buying or selling intentions.
Insider Transaction Report
Form 4
BELITE BIO, INCBLTE
Lin Yu-Hsin
DirectorChief Executive Officer
Transactions
- Other
Ordinary Share
[F1]2026-04-21+10,000→ 182,949 total
Footnotes (1)
- [F1]On September 15, 2025, the reporting person was granted an award of restricted stock units ("RSUs") which shall vest upon satisfaction of certain performance criteria. Such performance criteria was met on 04/21/2026, resulting in vesting of the RSUs as to 10,000 ordinary shares.
Signature
/s/ Yu-Hsin Lin|2026-04-23